EBM dla terapii skojarzonej nadciśnienia tętniczego na przykładzie wybranych badań z perindoprilem Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2013
Słowa kluczowe:
nadciśnienie tętnicze, terapia skojarzona, redukcja ryzyka
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze jest głównym czynnikiem ryzyka chorób układu sercowo-naczyniowego, zatem prawidłowe wartości ciśnienia tętniczego są istotnym celem prewencji chorób serca i naczyń. Wybór leków w terapii skojarzonej nadciśnienia tętniczego zależy od specyficznych punktów uchwytu substancji czynnej, które modyfikują czynniki ryzyka i zaawansowanie współistniejących chorób oraz zapobiegają uszkodzeniom narządowym. Artykuł skupia się na przeglądzie badań klinicznych dotyczących terapii skojarzonej nadciśnienia tętniczego. Analiza ta może stanowić punkt wyjścia dyskusji dotyczącej preferencji skojarzenia terapii hipotensyjnej, także w postaci preparatów złożonych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Balsam , P., & Grabowski , M. (2013). EBM dla terapii skojarzonej nadciśnienia tętniczego na przykładzie wybranych badań z perindoprilem . Medycyna Faktów , 6(2(19), 65-72. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2416
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M. et al.: Heart disease and stroke statistics 2011 update: a report from the American Heart Association. Circulation 2011; 123(4): e18-e209.
2. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood pressure 2009; 18(6): 308-47.
3. Widecka K.: Jaką rolę odegrały złożone leki hipotensyjne w poprawie skuteczności leczenia nadciśnienia tętniczego w Polsce? Nadciśnienie Tętnicze 2012; 16(4): 7.
4. Law M.R., Wald N.J., Morris J.K., Jordan R.E.: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326(7404): 1427.
5. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura A.: Zasady postępowania w nadciśnieniu tętniczym — 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 27.
6. Mancia G., Grassi G.: Systolic and diastolic blood pressure control in antihypertensive drug trials. Journal of hypertension. 2002; 20(8): 1461-4.
7. Feldman R.D., Zou G.Y., Vandervoort M.K., Wong C.J., Nelson S.A., Feagan B.G.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53(4): 646-53.
8. van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J. et al.: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. European Heart Journal 2012; 33(16): 2088-97.
9. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
10. Farsang C., Naditch-Brule L., Avogaro A., Ostergren J., Verdecchia P., Maggioni A. et al.: Where are we with the management of hypertension? From science to clinical practice. Journal of Clinical Hypertension 2009; 11(2): 66-73.
11. Bangalore S., Shahane A., Parkar S., Messerli F.H.: Compliance and fixed-dose combination therapy. Current Hypertension Reports 2007; 9(3): 184-9.
12. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. The New England Journal of Medicine 2001; 345(12): 870-8.
13. Dahlof B., Gosse P., Gueret P., Dubourg O., de Simone G., Schmieder R. et al.: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension 2005; 23(11): 2063-70.
14. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U. et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004-10.
15. Mourad J.J., Waeber B., Zannad F., Laville M., Duru G., Andrejak M. et al.: Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. Journal of Hypertension. 2004; 22(12): 2379-86.
16. Mogensen C.E., Viberti G., Halimi S., Ritz E., Ruilope L., Jermendy G. et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41(5): 1063-71.
17. Patel A., Group A.C., MacMahon S., Chalmers J., Neal B., Woodward M. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-40.
18. Chalmers J., Joshi R., Kengne A.P., MacMahon S.: Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. Journal of Hypertension Supplement 2008; 26(2): S11-5.
19. Farsang C., on Behalf Of The Picasso I: Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Pressure 2012. PubMed PMID: 23163322.
20. Karpov Iu A. [The FORTISSIMO Program: Advantages of Fixed Full Dose Combination of Perindopril Arginine and Indapamide in the Treatment of Poorly Controlled Arterial Hypertension]. Kardiologia 2013; 53(3): 37-43.
21. Pella D.: Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Pressure & Cardiovascular Prevention 2011; 18(3): 107-13.
22. Waeber B., Feihl F., Ruilope L.M.: Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 2009; 69(13): 1761-76.
23. Gradman A.H., Basile J.N., Carter B.L., Bakris G.L., American Society of Hypertension, Writing G.: Combination therapy in hypertension. Journal of Clinical Hypertension 2011; 13(3): 146-54.
24. Gradman A.H., Parise H., Lefebvre P., Falvey H., Lafeuille M.H., Duh M.S.: Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61(2): 309-18.
25. Wożakowska-Kapłon B., Filipiak K.J., Czarnecka D. et al.: Combination therapy in the management of hypertension – current problem in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiol. Pol. 2013; 71: 433-438.
2. Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulfield M.J. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood pressure 2009; 18(6): 308-47.
3. Widecka K.: Jaką rolę odegrały złożone leki hipotensyjne w poprawie skuteczności leczenia nadciśnienia tętniczego w Polsce? Nadciśnienie Tętnicze 2012; 16(4): 7.
4. Law M.R., Wald N.J., Morris J.K., Jordan R.E.: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326(7404): 1427.
5. Widecka K., Grodzicki T., Narkiewicz K., Tykarski A., Dziwura A.: Zasady postępowania w nadciśnieniu tętniczym — 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 27.
6. Mancia G., Grassi G.: Systolic and diastolic blood pressure control in antihypertensive drug trials. Journal of hypertension. 2002; 20(8): 1461-4.
7. Feldman R.D., Zou G.Y., Vandervoort M.K., Wong C.J., Nelson S.A., Feagan B.G.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53(4): 646-53.
8. van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J. et al.: Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. European Heart Journal 2012; 33(16): 2088-97.
9. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
10. Farsang C., Naditch-Brule L., Avogaro A., Ostergren J., Verdecchia P., Maggioni A. et al.: Where are we with the management of hypertension? From science to clinical practice. Journal of Clinical Hypertension 2009; 11(2): 66-73.
11. Bangalore S., Shahane A., Parkar S., Messerli F.H.: Compliance and fixed-dose combination therapy. Current Hypertension Reports 2007; 9(3): 184-9.
12. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. The New England Journal of Medicine 2001; 345(12): 870-8.
13. Dahlof B., Gosse P., Gueret P., Dubourg O., de Simone G., Schmieder R. et al.: Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. Journal of Hypertension 2005; 23(11): 2063-70.
14. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U. et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004-10.
15. Mourad J.J., Waeber B., Zannad F., Laville M., Duru G., Andrejak M. et al.: Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. Journal of Hypertension. 2004; 22(12): 2379-86.
16. Mogensen C.E., Viberti G., Halimi S., Ritz E., Ruilope L., Jermendy G. et al.: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41(5): 1063-71.
17. Patel A., Group A.C., MacMahon S., Chalmers J., Neal B., Woodward M. et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829-40.
18. Chalmers J., Joshi R., Kengne A.P., MacMahon S.: Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. Journal of Hypertension Supplement 2008; 26(2): S11-5.
19. Farsang C., on Behalf Of The Picasso I: Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. Blood Pressure 2012. PubMed PMID: 23163322.
20. Karpov Iu A. [The FORTISSIMO Program: Advantages of Fixed Full Dose Combination of Perindopril Arginine and Indapamide in the Treatment of Poorly Controlled Arterial Hypertension]. Kardiologia 2013; 53(3): 37-43.
21. Pella D.: Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. High Blood Pressure & Cardiovascular Prevention 2011; 18(3): 107-13.
22. Waeber B., Feihl F., Ruilope L.M.: Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 2009; 69(13): 1761-76.
23. Gradman A.H., Basile J.N., Carter B.L., Bakris G.L., American Society of Hypertension, Writing G.: Combination therapy in hypertension. Journal of Clinical Hypertension 2011; 13(3): 146-54.
24. Gradman A.H., Parise H., Lefebvre P., Falvey H., Lafeuille M.H., Duh M.S.: Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61(2): 309-18.
25. Wożakowska-Kapłon B., Filipiak K.J., Czarnecka D. et al.: Combination therapy in the management of hypertension – current problem in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiol. Pol. 2013; 71: 433-438.